营收情况 - 2023年第四季度，Qiagen公司营收为5.0916亿美元，同比增长2.3%[1] - 营收超出Zacks Consensus Estimate 0.99%，达到5.0416亿美元[2] 每股收益 - 每股收益为0.55美元，与去年同期的0.55美元相比持平[1] - 每股收益低于预期-1.79%，预期为0.56美元[2] 销售额情况 - 分子诊断营收为2.71亿美元[5] - 生命科学营收为2.38亿美元[6] - 样本技术销售额为1.64亿美元[7] - 其他产品销售额为1.9亿美元[8] - PCR/核酸扩增销售额为0.81亿美元[9] - 基因组学/NGS销售额为0.65亿美元[10] - 诊断解决方案销售额为1.8亿美元[11]

QIAGEN N.V. (QGEN) recently announced a collaboration with Penn State University, United States, to create a shared research and education facility for fast-developing microbiome sciences. The company will provide instruments and kits for preparing and processing microbial samples for the flagship project at Penn State’s Huck Institutes of the Life Sciences, “One Health Microbiome Center”, to support faculty and students.The latest development will significantly boost the company’s Life Sciences business ar ...

Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences. The university-industry partnership will serve as a beacon for this field by investigating research opportunities that address challenges and research gaps facing the microbiome, w ...

Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split. The repayment from existing cash reserves is expected to lead to an approximately 3% reduction in the number of issued shares (based on current share price). The terms of the syntheti ...

QIAGEN N.V. (QGEN) recently received FDA clearance for the NeuMoDx CT/NG Assay 2.0, growing its test menu for its integrated PCR-based clinical molecular testing systems NeuMoDx 96 and 288 in the United States. The Assay is designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the country. The latest development will significantly boost the company’s Molecular Diagnostics business.About QIAGEN’s PCR-Based Clinical Molecular Testing SystemsThe NeuM ...

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023. Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date/time: Wednesday, February 7, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.  Three options for joining the conference call Register for call back connect ...

QIAGEN’s (QGEN) business is expected to get a boost from its expanded test menu and growth-driving strategic collaborations. However, overdependence on relationships with collaborative partners and foreign exchange headwinds are major downsides. The stock carries a Zacks Rank #3 (Hold) currently.QIAGEN’s long-term business strategy involves entering into strategic alliances as well as marketing and distribution arrangements with academic, corporate and other partners relating to the development, commerciali ...

NeuMoDx CT/NG Assay 2.0获得美国FDA批准 - QIAGEN宣布NeuMoDx CT/NG Assay 2.0获得美国FDA批准，扩大了其在美国的PCR基因检测系统NeuMoDx 96和288的测试菜单[1] - 这一批准支持了NeuMoDx分子系统在美国的测试菜单扩展，同时也建立在系统上16个欧盟认证的体外诊断(CE-IVD)测试的基础上，这是市场上接受CE-IVD标志的国家中最广泛的之一[2] - NeuMoDx 96和288分子系统是完全自动化的连续随机访问分析仪，可在约一小时内提供结果，这些系统提取DNA以分离目标核酸，然后进行实时聚合酶链反应(RT-PCR)[4]

Venlo, the Netherlands, Jan. 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA))) today announced a plan to return up to approximately $300 million (maximum EUR 273 million) to shareholders through a synthetic share repurchase that combines a direct capital repayment with a reverse stock split. QIAGEN has decided to implement the maximum $300 million value of the mandate given at the Annual General Meeting in June 2023, where shareholders gave virtually unanimous approval f ...

QIAGEN在中东地区业务扩张 - QIAGEN宣布在中东地区进行重大业务扩张，包括在沙特阿拉伯利雅得开设区域总部，并与沙特阿拉伯卫生部签署谅解备忘录[1] QIAGEN在沙特阿拉伯设立本地数据中心 - QIAGEN将在沙特阿拉伯设立本地数据中心，支持先进的生物信息学，包括在国内建立分子数据分析中心，协助消除脑膜炎，支持宫颈癌筛查计划，以及开展国家潜伏性结核病筛查计划[3] QIAGEN向阿曼提供数十万份试剂 - QIAGEN将通过其商业合作伙伴Taiba Medserv LLC向阿曼提供数十万份QuantiFERON-TB Gold Plus试剂，支持该国的潜伏性结核病筛查计划[4]